Cargando…
Synthetic microbial consortia for the treatment of Clostridioides difficile infection in mice model
Clostridioides difficile infection (CDI) as of recent has become a great concern to the impact on human health due to its high hazardous risk and rate of recurrence. Live bacterial therapeutics is a promising method to treat or prevent CDI. Here, a synthetic microbial consortia (SMC) B10 was constru...
Autores principales: | Liu, Jinqiu, Zhu, Wei, Lessing, Duncan James, Chu, Weihua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10527189/ https://www.ncbi.nlm.nih.gov/pubmed/37602713 http://dx.doi.org/10.1111/1751-7915.14333 |
Ejemplares similares
-
Synthetic bacterial consortia transplantation for the treatment of Gardnerella vaginalis-induced bacterial vaginosis in mice
por: Li, Yunxia, et al.
Publicado: (2023) -
Majority sensing in synthetic microbial consortia
por: Alnahhas, Razan N., et al.
Publicado: (2020) -
Design and construction of synthetic microbial consortia in China
por: Ding, Ming-Zhu, et al.
Publicado: (2016) -
Synthetic Oligosaccharide-Based
Vaccines Protect Mice
from Clostridioides difficile Infections
por: Broecker, Felix, et al.
Publicado: (2019) -
The microbial diversity following antibiotic treatment of Clostridioides difficile infection
por: Binyamin, Dana, et al.
Publicado: (2021)